NASDAQ:IPXL - Impax Laboratories Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.30 0.00 (0.00 %)
(As of 05/4/2018)
Previous Close$18.30
Today's Range$17.40 - $18.95
52-Week Range$13.05 - $25.70
Volume3.04 million shs
Average Volume945,265 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Impax Generics and Impax Specialty Pharma. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements. The Impax Specialty Pharma segment engages in the development, sale, and distribution of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson's disease, and post-herpetic neuralgia, as well as other select specialty segments. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals USA, Inc. to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1995 and is headquartered in Hayward, California.

Receive IPXL News and Ratings via Email

Sign-up to receive the latest news and ratings for IPXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IPXL



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A

Impax Laboratories (NASDAQ:IPXL) Frequently Asked Questions

What is Impax Laboratories' stock symbol?

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

How were Impax Laboratories' earnings last quarter?

Impax Laboratories (NASDAQ:IPXL) released its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.03. The specialty pharmaceutical company had revenue of $206.40 million for the quarter, compared to the consensus estimate of $208.38 million. The company's quarterly revenue was down 9.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.37 EPS. View Impax Laboratories' Earnings History.

What price target have analysts set for IPXL?

2 brokers have issued 1 year price objectives for Impax Laboratories' stock. Their forecasts range from $20.00 to $27.00. On average, they expect Impax Laboratories' share price to reach $23.50 in the next year. This suggests a possible upside of 28.4% from the stock's current price. View Analyst Price Targets for Impax Laboratories.

What is the consensus analysts' recommendation for Impax Laboratories?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Impax Laboratories in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Impax Laboratories.

Has Impax Laboratories been receiving favorable news coverage?

Media headlines about IPXL stock have trended somewhat negative this week, according to InfoTrie. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Impax Laboratories earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.

Who are some of Impax Laboratories' key competitors?

What other stocks do shareholders of Impax Laboratories own?

Who are Impax Laboratories' key executives?

Impax Laboratories' management team includes the folowing people:
  • Mr. Bryan M. Reasons, Sr. VP of Fin. & CFO (Age 51)
  • Mr. Mark A. Schlossberg, Sr. VP, Gen. Counsel & Corp. Sec. (Age 57)
  • Mr. Michael J. Nestor, Pres of Impax Specialty Pharma Division (Age 65)
  • Mr. Douglas S. Boothe, Pres of Impax Generics Division (Age 54)
  • Mr. Paul M. Bisaro, CEO, Pres & Director (Age 57)

How do I buy shares of Impax Laboratories?

Shares of IPXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Impax Laboratories' stock price today?

One share of IPXL stock can currently be purchased for approximately $18.30.

What is Impax Laboratories' official website?

The official website for Impax Laboratories is

How can I contact Impax Laboratories?

Impax Laboratories' mailing address is 30831 HUNTWOOD AVENUE, HAYWARD CA, 94544. The specialty pharmaceutical company can be reached via phone at 510-476-2000 or via email at [email protected]

MarketBeat Community Rating for Impax Laboratories (NASDAQ IPXL)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  383 (Vote Outperform)
Underperform Votes:  542 (Vote Underperform)
Total Votes:  925
MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe IPXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel